Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
| Autor: | Heng-Cheng Chu, Yu-Shiuan Lin, Te-Chao Fang, Chih-Chin Kao, Yi No Kang, Mai-Szu Wu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
hepatitis C virus
medicine.medical_specialty Anemia lcsh:Medicine Renal function Lower risk urologic and male genital diseases Article 03 medical and health sciences 0302 clinical medicine Internal medicine direct-acting antiviral agents (DAAs) medicine 030212 general & internal medicine business.industry lcsh:R General Medicine Hepatitis C medicine.disease female genital diseases and pregnancy complications Discontinuation Meta-analysis Relative risk 030211 gastroenterology & hepatology business chronic kidney disease Kidney disease |
| Zdroj: | Journal of Clinical Medicine Volume 7 Issue 10 Journal of Clinical Medicine, Vol 7, Iss 10, p 314 (2018) |
| ISSN: | 2077-0383 |
| Popis: | The effectiveness and safety of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV) patients with renal insufficiency remain controversial. Therefore, this network meta-analysis aims to assess effectiveness and safety of DAAs in populations with different renal function. The pooled data were obtained from Cochrane Library, EMBASE, PubMed, and Web of Science. Thirteen studies recruited 6884 patients with hepatitis C infection and reported their outcomes in relation to different levels of renal function after treatment with DAAs. The results showed no difference in the virologic responses among patients with different renal function. Regarding safety, whereas in patients without chronic kidney disease (CKD) or with early CKD DAAs were associated with a risk ratio (RR) of 0.14 (95% confidence interval (CI), 0.04 to 0.43) for renal disorder, increased risk of renal function deterioration was found in advanced-CKD patients, though this effect may be related to the natural course of advanced CKD. Similarly, patients without CKD or with early CKD showed a lower risk of anemia (RR, 0.34 95% CI, 0.20 to 0.57) and discontinuation (RR, 0.41 95% CI, 0.39 to 0.56) than patients with advanced CKD. The efficacy of DAAs for HCV treatment was comparable in patients with advanced CKD and in those with early CKD or without CKD. However, the safety of DAAs should be verified in future studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|